Advisor Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Advisor Group’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$15K	Sell	2,916 -2,982	-51%	-$15.8K	﹤0.01%	4124
2019 Q3	$30K	Sell	5,898 -2,051	-26%	-$10.2K	﹤0.01%	3728
2019 Q2	$49K	Sell	7,949 -3,280	-29%	-$15.8K	﹤0.01%	3384
2019 Q1	$53K	Sell	11,229 -1,422	-11%	-$6.43K	﹤0.01%	3348
2018 Q4	$53K	Buy	12,651 +12,158	+2,466%	+$61.9K	﹤0.01%	3147
2018 Q3	$3K	Hold	493	–	–	﹤0.01%	4790
2018 Q2	$4K	Sell	493 -27	-5%	-$206	﹤0.01%	4506
2018 Q1	$4K	Buy	520 +13	+3%	+$86	﹤0.01%	4530
2017 Q4	$3K	Hold	507	–	–	﹤0.01%	4626
2017 Q3	$4K	Sell	507 -6,872	-93%	-$43.6K	﹤0.01%	4389
2017 Q2	$50K	Buy	7,379 +6,796	+1,166%	+$50.2K	﹤0.01%	2864
2017 Q1	$6K	Buy	583 +199	+52%	+$1.99K	﹤0.01%	4068
2016 Q4	$3K	Sell	384 -978	-72%	-$7.23K	﹤0.01%	4161
2016 Q3	$9K	Buy	+1,362	New	+$8.23K	﹤0.01%	3642

Other funds holding PGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Advisor Group's PGNX Position: Q4 2019 in Review

Advisor Group reduced its Progenics Pharmaceuticals Inc (PGNX) stake by 51% in Q4 2019, selling an estimated $15.8K and leaving 2,916 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #4124.

Advisor Group first reported a position in PGNX in Q3 2016 and has held it in 14 quarters since. The position peaked at $53K in Q1 2019. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

Advisor Group held 2,916 shares of Progenics Pharmaceuticals Inc worth $15K as of Q4 2019.
Advisor Group sold 2,982 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $15.8K.
Progenics Pharmaceuticals Inc made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4124 holding.
Advisor Group first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and has held it in 14 quarters since.
Advisor Group's Progenics Pharmaceuticals Inc position peaked at $53K in Q1 2019.
128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.